ESMO 2017: Anti-programmed death 1 receptor drug pembrolizumab has significant antitumor activity in carcinoid and pancreatic neuroendocrine tumours

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • In the KEYNOTE-028 trial, pembrolizumab, an anti-programmed death 1 receptor drug, provided meaningful antitumour activity in carcinoid and pancreatic neuroendocrine tumours.

Why this matters

  • Programmed death-ligand 1 expression is associated with a more aggressive disease....